ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours by Wilzen, Annica et al.
Wilzén et al. Molecular Cancer 2013, 12:70
http://www.molecular-cancer.com/content/12/1/70RESEARCH Open AccessERBB3 is a marker of a ganglioneuroblastoma/
ganglioneuroma-like expression profile in
neuroblastic tumours
Annica Wilzén1, Cecilia Krona2, Baldur Sveinbjörnsson2,3, Erik Kristiansson4, Daniel Dalevi4, Ingrid Øra5,
Katleen De Preter6, Raymond L Stallings7, John Maris8, Rogier Versteeg9, Staffan Nilsson4, Per Kogner2
and Frida Abel1*Abstract
Background: Neuroblastoma (NB) tumours are commonly divided into three cytogenetic subgroups. However, by
unsupervised principal components analysis of gene expression profiles we recently identified four distinct
subgroups, r1-r4. In the current study we characterized these different subgroups in more detail, with a specific
focus on the fourth divergent tumour subgroup (r4).
Methods: Expression microarray data from four international studies corresponding to 148 neuroblastic tumour
cases were subject to division into four expression subgroups using a previously described 6-gene signature.
Differentially expressed genes between groups were identified using Significance Analysis of Microarray (SAM). Next,
gene expression network modelling was performed to map signalling pathways and cellular processes representing
each subgroup. Findings were validated at the protein level by immunohistochemistry and immunoblot analyses.
Results: We identified several significantly up-regulated genes in the r4 subgroup of which the tyrosine kinase
receptor ERBB3 was most prominent (fold change: 132–240). By gene set enrichment analysis (GSEA) the
constructed gene network of ERBB3 (n = 38 network partners) was significantly enriched in the r4 subgroup in all
four independent data sets. ERBB3 was also positively correlated to the ErbB family members EGFR and ERBB2 in all
data sets, and a concurrent overexpression was seen in the r4 subgroup. Further studies of histopathology
categories using a fifth data set of 110 neuroblastic tumours, showed a striking similarity between the expression
profile of r4 to ganglioneuroblastoma (GNB) and ganglioneuroma (GN) tumours. In contrast, the NB
histopathological subtype was dominated by mitotic regulating genes, characterizing unfavourable NB subgroups
in particular. The high ErbB3 expression in GN tumour types was verified at the protein level, and showed mainly
expression in the mature ganglion cells.
Conclusions: Conclusively, this study demonstrates the importance of performing unsupervised clustering and
subtype discovery of data sets prior to analyses to avoid a mixture of tumour subtypes, which may otherwise give
distorted results and lead to incorrect conclusions. The current study identifies ERBB3 as a clear-cut marker of a
GNB/GN-like expression profile, and we suggest a 7-gene expression signature (including ERBB3) as a complement
to histopathology analysis of neuroblastic tumours. Further studies of ErbB3 and other ErbB family members and
their role in neuroblastic differentiation and pathogenesis are warranted.
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Peripheral neuroblastic tumours (NT’s) are derived
from developing neuronal cells of the sympathetic ner-
vous system and are the most frequent extracranial
solid tumours of childhood. NT’s are composed of vari-
able proportion of neuroblasts (neuronal lineage) and
Schwannian cells (glial lineage), and are classified into
histopathological categories according to the presence
or absence of Schwannian stromal development, differ-
entiation grade of the neuroblasts, and their cellular
turnover index. According to the International Neuro-
blastoma Pathology Classification (INPC - Shimada system)
[1], the three subtype categories and their subtypes
are: 1) Neuroblastoma (NB), Schwannian stroma-poor;
2) ganglioneuroblastoma (GNB), intermixed (Schwannian
stroma-rich) or nodular (composite Schwannian stroma-
rich/stroma-dominant and stroma-poor); 3) ganglioneuroma
(GN), Schwannian stroma-dominant. Neuroblastoma
exhibit an extreme clinical and biological heterogeneity,
and patients are assigned to risk groups based on several
criteria including stage [2,3], age [4], histological category
and grade of tumour differentiation (histopathology) [5],
the status of the MYCN oncogene [6], chromosome 11q
status [7], and DNA ploidy [8] as the most highly statisti-
cally significant and clinically relevant factors [9]. One-
half of NB patients have metastatic disease at diagnosis
(INSS stage 4 or INRGSS stage M). All metastatic tu-
mours with MYCN amplification (MNA) are aggressive
and considered being high-risk tumours [9], whereas chil-
dren with metastatic disease without MNA (approxi-
mately 65%) have variable clinical behaviours depending
on age at diagnosis, histopathology, and other genetic fac-
tors. Based upon cytogenetic profiles, previous studies
have categorized NB tumours into three major subtypes
[10,11]: Subtype 1 representing favourable tumours with
near triploidy and high expression of the Neurotrophic
receptor TrkA (or NTRK1), mostly encompassing non-
metastatic NB stages 1 and 2; subtype 2A representing un-
favourable NB stages 3 and 4, with 11q deletion (Del11q)
and 17q gain (Gain17q) but without MNA; subtype 2B
representing unfavourable widespread NB stages 3 and 4
with MNA often together with 1p deletion (Del1p) and
Gain17q. Several gene sets are shown to discriminate the
molecular subgroups and risk groups by mRNA and
microRNA expression profiling in neuroblastic tumours
[12-21]. A recent expression analysis by our research
group identified the three cytogenetically defined subtypes
(1, 2A, and 2B) by unsupervised clustering, but further in-
dicated the existence of a fourth divergent subgroup [12].
Moreover, we identified a 6-gene signature including ALK,
BIRC5, CCND1, MYCN, NTRK1, and PHOX2B to suc-
cessfully discriminate these four subgroups [12]. The
fourth (r4) subgroup encompassed tumours characterized
by Del11q and high expression of genes involved in thedevelopment of the nervous system, but showed low ex-
pression of ALK. Approximately 7-9% of sporadic NB
cases show inherent ALK mutations [22,23], and ALK
overexpression, both in its mutated and wild type form,
is demonstrated to define a poor prognosis in NB pa-
tients [24]. In relation to this our previous findings sug-
gests the Type 2A (r2) and Type 2B (r3) subgroups,
which both display high ALK expression, to be driven
by the ALK pathway. In contrast, the r4 subgroup
displaying low expression of all six genes of the signa-
ture, is suggested to be driven by an alternative onco-
genesis pathway.
In the present study we aimed to further investigate
the expression profiles of the four subgroups, and r4 in
particular. By differential expression analysis and reverse
engineering we found ERBB3 and its network members
to be significantly overrepresented within the r4 tumour
subgroup. Moreover, two other ErbB family members,
ERBB2 and EGFR, were found to show concurrently
higher expression. In contrast, unfavourable neuroblast-
oma subgroups (r2 and r3) were specifically character-
ized by G2/M cell cycle transition and mitotic regulating
genes. By expression analysis of histopathology categor-
ies (i.e. NBs, GNBs, and GNs) we found the r4 subgroup
to show an identical expression profile to GNB/GN
types, and overexpression of ErbB3 was also confirmed
at the protein level in GN tumours. We conclude that
the ERBB-profile (high expression of EGFR, ERBB2 and
ERBB3) defines a ganglion-rich neuroblastic tumour
sub-set.
Results
Differential expression in r-subgroups
To explore subgroup-specific characteristics we performed
a differential expression analysis by SAM. Thirty-seven
tumour cases from three studies were pre-processed in
two separate data sets (data set 1, n = 14, and data set
2, n = 23, Table 1), and both data sets were divided into
four r-subgroups based on rules according to the previ-
ously described 6-gene signature (6-GeneSig, Additional
file 1) [12]. Six SAM pair-wise comparisons between r-
subgroups were performed on each data set separately,
and the 1000 most significant genes (according to
descending SAM d-score) with a fold change above 2, were
extracted to create SAMintersect gene lists representing both
data sets (Additional file 2). The r2 versus r1 group
comparison showed 122 differentially expressed genes
present in lists from both data sets, and the r3 versus
r1 group comparison showed 496 overlapping genes
(Figure 1A). The r4 subgroup showed the highest
proportion of significant differentially expressed genes
compared to all the other subgroups in both data sets
(number of overlapping genes ranging between 503
and 669, Figure 1A).
Table 1 Data sets used in the current study
Name Reference # Total cases Description Analysis
platform
# Analysis
cases
Analysis
groups
Purpose of study
Data
set 1
DePreter [53] 17 Neuroblastoma Affy HU133A
(pre-amplified)
14 r-groups (r1-r4) Differential mRNA expression of
subgroups
Data
set 2
McArdle [54] 22 Neuroblastic Affy HU133A 17 r-groups (r1-r4) Differential mRNA expression of
subgroups
Wilzén [55] 8 Neuroblastoma Affy HU133A 6 r-groups (r1-r4) Differential mRNA expression of
subgroups
Data
set 3
Wang [56] 101 Neuroblastoma Affy HGU95Av 67 r-groups (r1-r4) Verification of subgroup findings; Gene
network construction
Data
set 4
Versteeg [57] 110 Neuroblastic Affy
HU133plus2
110 Histology groups
(GN, GNB, NB)
Differential mRNA expression of
histology subgroups
Data
set 5
Kogner - 12* Neuroblastic IHC, WB 8 (IHC), 9
(WB)
Histology groups
(GN, NB)
Protein expression validation in
histology subgroups
SAM Significance Analysis of Microarray. Neuroblastic = mixed pool of neuroblastoma (NB), ganglioneuroblastoma (GNB), and ganglioneuroma (GN). Affy
Affymetrix, IHC Immunohistochemistry, WB Western blotting.* One case overlaps with data set 2 (case "NBS1" in data set 2 = case ′6′ in data set 5).
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defined subgroup Type 1) was found to mainly involve
nervous system developmental and catecholamine meta-
bolic process related genes. In the MNA-specific subgroup
r3 (corresponding to Type 2B), KIF15 was the most sig-
nificantly up-regulated gene (fold = 15) while CUX2
showed the highest expression fold change (fold = 17).
The MYCN gene was found on the 74th position of up-
regulated genes (fold = 9), and NTRK1 was identified as
the most significantly down-regulated gene within r3 com-
pared to r1 (fold = 80, Additional file 2). Also, LMO3 and
PHGDH were found to be specifically up-regulated in the
r3 subgroup compared to the other subgroups. High ex-
pression of ALK was found in both the r2 (2-fold) and r3
(5-fold) subgroups compared to the favourable r1 sub-
group. Moreover, r2 and r3 also showed up-regulation of
several G2/M cell cycle transition and mitotic checkpoint
related genes (e.g. AURKA, BRCA1, BUB1B, CCNA2,
CCNB1, KIF15, MCM2, MCM3, and MCM5 etc.), which
in contrast showed a significant down-regulation in the r4
subgroup. In line with this, a Gene Ontology (GO) search
identified “cell cycle” as the most significant process accu-
mulated in the SAMintersect gene lists of the r2 and r3
subgroups (Figure 1B, Additional file 3). The apparent
overrepresentation of cell cycle-related genes in sub-
groups r2 and r3 encouraged us to investigate enrich-
ment of other cell cycle key players and networks in our
SAM gene lists.
Differential expression in subgroup r4
Among the 10 most significantly up-regulated genes in the
r4 subgroup in data sets 1 and 2, the following eleven genes
were found; ABCA8, APOD, ASPA, CDH19, ERBB3,
FXYD1, ITIH5, MAL, PLP1, S100B, and ST6GALNAC2.
According to the GO search, these genes are mainly involved
in nervous system development, multicellular organismaldevelopment, and response to wounding (Figure 1B,
Additional file 3). ERBB3 was found as the “top-one”
up-regulated gene in r4 versus r3 with a 240-fold ex-
pression. ERBB3 encodes a transmembrane tyrosine
kinase receptor, which has previously been associated
with cancer in a large number of studies (>500 publica-
tions). ErbB3 is activated through dimerization to one
of its four structurally related family members; EGFR,
ErbB2, or ErbB4. ErbB-family members are often co-
expressed, and thus we found it relevant to investigate
their expression level relationships in our four neuroblatic
data sets. We found a positive significant correlation of
ERBB3 to the EGFR and ERBB2 family members, and a
negative correlation to all genes of the 6-GeneSig in all four
data sets (p < 0.05, Additional file 4). Also, EGFR and
ERBB2 showed a significant up-regulation in r4 subgroups
of most data sets (p < 0.05, Additional file 2). ERBB3 show
several similarities to ALK, encoding the NB familial gene
[25], and thus made a good candidate gene with potential
role in the tumour development of r4 tumour types.
Among the down-regulated genes in the r4 sub-
group CACNA2D3 was the most significant in com-
parison to the r1 subgroup (50-fold change). This
gene was also found to be the 25th most down-
regulated gene in the r3 subgroup compared to r1
(Additional file 2). Since both the r3 and r4 sub-
groups are previously found to show unfavourable
outcome and poor survival [12], and the CACNA2D3
gene is located in the 3p21.1- locus commonly de-
leted in many NB tumours, this encouraged us to
further screen the SAMintersect gene lists for other
conceivable and previously reported tumour suppres-
sor (TS) candidate genes. Out of 33 previously
reported TS candidate genes, 15 were present among
the SAMintersect gene lists from data sets 1 and 2
(Additional file 5).
Figure 1 Analyses of SAM gene lists. A. Venn diagram of SAM results. SAM results from six r-group comparisons are presented for the DePreter
and McArdle/Wilzén data sets. # cases = Total number of cases included in each comparison from each data set; # overlapping genes = Total
number of genes overlapping between the original SAM gene lists (1000 genes from each direction) from data set 1 and 2, constituting the
SAMintersect gene lists; # significant genes = Total number of overlapping significant genes (combined p-value) using a cut-off of p < 6.25E-06,
which correspond to a Bonferroni corrected p-value of p < 0.05; # genes FC > 5 = Total number of overlapping genes showing a combined fold
change (FC) above 5 in each comparison. B. Venn diagram of GO functional themes. The Biological Networks Gene Ontology (BiNGO) tool in
Cytoscape was utilized to map the predominant functional themes of the SAM gene lists. The most dominating Gene Ontology (GO) terms from
each SAM comparison are presented from two differential expression directions; "up" (left panel) or "down" (right panel). Upper panel: r-group
comparisons from all three data sets; data set 1 (DePreter), data set 2 (McArdle/Wilzén), and data set 3 (Wang). Lower panel: Histopathology
group comparisons in data set 4 (Versteeg) The full GO search results are presented in Additional file 3. C. Gene network frequencies. The heat
map table represents the percentage of network genes out of the total number of genes in the gene networks (marked in grey). The total
number of genes in the SAM gene lists are presented to the right. The upper panel “Data sets 1 & 2_comb” represents combined intersect gene
lists from the two data sets, and the other panels represents gene lists from the 1000 most differentially expressed genes in each direction.
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analysis (GSEA)
Network modelling reveals the regulatory relationships
among genes and can provide a systematic understanding
of molecular mechanisms underlying biological processes.
A variety of algorithms have been developed, and in the
current study we chose the ARACNE algorithm [26] for re-
construction of seven networks (ALK, BIRC5, CCND1,
ERBB3, MYCN, NTRK1, PHOX2B) from the Wang data set(n = 102), since this method has a documented high per-
formance [27]. Also, 4850 pre-existing curate gene sets (c2)
from the Molecular Signatures Database (MSigDB) were se-
lected (Additional file 6). We subsequently analysed the lists
of differential expressed genes for enrichment of these 4857
gene networks. The SAMintersect lists of genes up-regulated
in the r4 group were found to comprise 17 out of 38 part-
ners (~ 45%) of the ARACNE_ERBB3 network (Figure 1C),
which was significantly verified by GSEA (p < 0.001,
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tween 20% and 58%) of the ARACNE_BIRC5 network part-
ners (n = 45, Additional file 6) were found among the up-
regulated genes of r2 and r3 tumour subgroups, which was
also significant by GSEA (p < 0.001, Additional file 7). A
GO search of the BIRC5 network partners suggested a roleFigure 2 Analyses of the ERBB3 gene network. Gene network of ERBB3
r-groups (data sets 1–3) and histopathology groups (data set 4). Nodes are
Grey = Not affected. Upper panel: Data sets 1 and 2 (DePreter and McArd
and r4 vs. r3). Only genes that were common in both data set 1 and 2 with
panel: Data set 3 (Wang) presenting three r-group comparisons (r4 vs. r1, r
gene list representing the 1000 most differentially expressed (ranked after s
histopathology group comparisons (GNB vs. NB and GN vs. NB). Genes incl
differentially expressed (ranked after significance). Gene set enrichment ana
sorting mode = real, sorted in descending order. NES = Normalized enrich
results (see Additional file 7).in mitosis (GO terms: cell cycle, nucleosome assembly,
chromatin assembly, protein-DNA complex assembly, nu-
cleosome organization, mitotic cell cycle, cell cycle phase,
DNA packaging, M phase, and cell cycle process, data not
shown). Other cell-cycle or mitotic related gene sets found
to be enriched among the r2 and r3 subgroups were e.g.(n = 38) for all data sets showing differentially expressed genes of
coloured as follows: Red = Up-regulated, Green = Down-regulated,
le/Wilzén) presenting three r-group comparisons (r4 vs. r1, r4 vs. r2,
fold change > 2 were included (i.e. SAMintersect gene lists). Middle
4 vs. r2, and r4 vs. r3). Genes included were those present in SAM
ignificance). Lower panel: Data set 4 (Versteeg) presenting two
uded were those present in SAM gene list representing the 1000 most
lysis (GSEA) plots of the ERBB3 network are according to gene list
ment score, NOM p-val. = Nominal p-value, according to the GSEA
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WHITFIELD_CELL_CYCLE_LITERATURE, REACTOME
_CELL_CYCLE_MITOTIC, REACTOME_CELL_CYCLE_
CHECKPOINTS curate gene sets (Additional file 7).
Verification of gene network modelling and differential
expression analysis
The differential expression profiles of the r-subgroups
were verified by replicating the study using the Wang
data set (n = 67 cases, Table 1). The outcomes of SAM
were in consistence with previous findings, showing
the ERBB3 gene to be significantly up-regulated and its
gene-network partners to be significantly overrepre-
sented in the r4 subgroup (Figure 1C, Figure 2). Also,
several other previously identified r4-specific genes,
APOD, CDH19, FXYD1, and S100B, were found among
the 1000 most significantly up-regulated genes. In con-
cordance with the previous analysis, we found the ex-
pression of CUX2 (fold = 5), LMO3 (fold = 2.7) and
PHGDH (fold = 1.9) to be significantly higher in the
MNA subgroup (r3) compared to the favourable subset
(r1). In addition, cell cycle-related genes dominated the
r2 and r3 subgroups, and this was significantly proven
by GSEA of the BIRC5 network and other cell cycle net-
works (p < 0.001, Additional file 7).
To confirm the robustness of the ARACNE constructed
gene networks, we selected the r3 versus r1 comparisons in
data sets 1 and 2 to investigate the expected overrepresen-
tation of MYCN- and NTRK1-network partners. Fourteen
genes out of 40 (35%) of the ARACNE_MYCN network
were found in the up-regulated gene lists, while eight out of
40 (20%) genes were found in the down-regulated gene
lists, demonstrating an accumulation of the ARACNE_
MYCN network in the r3 subgroup (Figure 1C, Additional
files 7 and 8). Also, an accumulation of the ARACNE_
NTRK1 network was found in the opposite direction. Out
of 62 genes composing the ARACNE_NTRK1 network, 28
genes (~ 45%) were among the 1000 most down-regulated
genes in r3, which was significant by GSEA (Additional files
7 and 8). According to significance by SAM, the NTRK1
gene was the “top-one” down-regulated gene within the r3
versus r1 subgroup comparison in both data sets (fold
change: >70, Figure 1C, Additional file 2). From these facts
we conclude our study design to be substantial, and the
constructed gene networks by ARACNE to be reliable and
highly representative.
In addition, we checked the enrichment of network part-
ners to the 6-GeneSig (ALK, BIRC5, CCND1, MYCN,
NTRK1, and PHOX2B) and found the network representa-
tions to be in concordance with the 6-GeneSig expression
levels in r-subgroups (Additional file 7). The credibility of
ARACNE constructed networks were also tested by litera-
ture verification, and seven out of 38 transcriptional con-
nections of the ERBB3-network as well as 11 out of 40transcriptional connections of the MYCN-network were
verified to have a functional relationship (data not shown).
This demonstrates the robustness of the computationally
inferred network analysis.
Differential expression analysis of histopathology groups
(data set 4)
To further explore the ERBB3 expression among other
neuroblastic tumour we utilized the R2 database
(hgserver1.amc.nl), and found indications of high ERBB3
expression in GNB and GN tumours. To investigate this
finding in more detail, we performed a differential ex-
pression analysis of the histopathology subtypes in the
Versteeg 110 data set (n = 110, Table 1). As expected, the
ERBB3 gene and networks partners were significantly
enriched in GNB and GN tumours compared to NB
(Figure 1C, Additional file 7). The highest enrichment of
the ERBB3-network was found in GN tumours, with 18
up-regulated genes out of 38 (p < 0.001, Figure 2). In
contrast, cell cycle-related genes and gene networks
significantly dominated the NB types, including the
ARACNE_BIRC5 network (Additional files 2 and 7).
Subgroup-specific expression profiles
ErbB family member genes (ERBB-genes; EGFR, ERBB2,
and ERBB3) and 15 previously reported tumour suppres-
sor candidate genes (TS-genes) were next studied by heat
maps in all four data sets (Figure 3). Most TS candidate
genes were down-regulated in the MNA-specific r3 sub-
group only. However, the CTNNBIP1 and KIF1B tran-
scripts were also found to be down-regulated in both r3
and r4 subgroups, and the TFAP2B transcript was specific-
ally down-regulated in the r4 subgroup alone (Figure 3,
Additional file 2). Overall, the expression profiles of the 6-
GeneSig genes, ERBB-genes, and TS-genes (25 genes in
total) among r-subgroups were very similar between data
sets. Moreover, the expression profiles of the GNB/GN tu-
mours were identical to the previously detected r4 sub-
groups of NB (Figure 3). These results strongly indicate
that the same cellular pathways are active in r4 and GNB/
GN tumours types, hence the ERBB-gene profile most
likely represents a more differentiated subset of tumours.
Verification of ErbB3 at protein level (data set 5)
To validate the biological significance of the ERBB3 enrich-
ment in the expression profiles of GN tumours, the ErbB3
protein expression was investigated by immunohistochem-
istry (IHC) and western blot (WB) analysis. The IHC was
performed on formalin-fixed and paraffin-embedded (FFPE)
tissue slides from four GN and four NB tumours by using
antibodies specific for Sox10 ([N-20], Santa Cruz Biotech-
nology) and ErbB-3 ([RTJ2], Abcam) respectively. The IHC
showed ErbB3 to be mainly expressed in mature ganglion
cells, whereas Sox10 was expressed in both ganglion and
Figure 3 Heat maps of r-subgroups. Heat map of the 6-GeneSig (ALK, BIRC5, CCND1, MYCN, NTRK1, and PHOX2B), ERBB-genes (EGFR, ERBB2, and
ERBB3) and 15 TS-genes (Tumour suppressor candidate genes) for all four data sets. The heat map colour scale is based on standard deviations
(sd) of all cases in each data set separately, and ranges from sd = 2 (red) to sd = −2 (green). The lower panel represents clinical and biological
markers: Histopathology, NB = Neuroblastoma, GNB = ganglioneuroblastoma, GN = ganglioneuroma; Stage INSS, clinical stages 1–4, and 4S
according to the international staging system, na = not available; Event = dead of disease, MNA = MYCN amplification, Del1p = 1p deletion,
Del11q = 11q deletion, Gain17q = gain of 17q. Colour coding: white = no event, black = event, grey = not available.
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Figure 4 Protein expression validation of ErbB3. A. Immunohistochemistry (IHC) assessment of case 2 showing ErbB3 expression in the
mature ganglion cells, and Sox10 expression in both ganglion and schwannian cells. Tumour tissue sections were stained using horseradish
peroxidase (HRP) secondary antibodies. The right panel shows the Sox10 and ErbB3 expression results from all IHC assessments performed,
y = yes, n = no expression. B. Colocalization study of ErbB3 and Sox10, showing ErbB3 expression mainly in ganglion cells. Tumour tissue sections
were simultaneously fluorescently stained using anti-goat Alexa Fluor 594 (Sox10, red) and anti-mouse Alexa Fluor 488 (ErbB3, green), and Dapi
(DNA, blue). C. High protein levels in GN tumours shown by Western blot of ErbB3. Primary antibodies used in studies: Sox10 ([N-20], Santa Cruz
Biotechnology), and ErbB-3 ([RTJ2], Abcam), which binds to both phosphorylated and unphosphorylated forms. Case 6 was also included in the
microarray analysis (NBS1, data set 2). Clinical data: NB = neuroblastoma, GNB = ganglioneuroblastoma, GN = ganglioneuroma; INSS stage [2];
INRGSS stage [3]: L = Localised, L1/L2 (INSS 1, 2, 3); M = Metastatic (INSS 4); Outcome: NED = No evidence of disease (white); AWD = Alive with
disease (grey); DOD = Dead of disease (black); MNA (MYCN-amplification), black = yes, white = no, na = not applicable.
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ellite cells, as well as schwannian cells were also Sox10
immunopositive (data not shown).
Immunoblot analysis was performed on five GN and four
NB in total (data set 5, Table 1). Out of the five investigated
GN cases, four corresponded to the GN cases examined by
IHC. In addition, the WB analysis also included one NB
encompassed in the microarray analysis (case 6 corre-
sponding to NBS1 in data set 2). The same antibody as for
IHC ([RTJ2], Abcam) directed against the cytoplasmic re-
gion of ErbB3 was chosen in order to detect several
isoforms of the protein as well as post-translationally modi-
fied and unmodified forms. Overall, ErbB3 expression
levels were high and clearly enriched in the GN subset
compared to the NB subset, which showed no detectable
levels of ErbB3. Moreover, case 6/NBS1 previously
displaying no or very low expression of ERBB3 by micro-
array analysis (data set 2, Figure 3), showed no detectable
levels of ErbB3 at protein level by immunoblot analysis.
Only one of the NB tumours (case 9) showed a strongErbB3 signal. However, this case was a localized INSS stage
3 with favourable biology, later histopathologically classi-
fied as a GNB. Moreover, only the lower molecular weight
band was visible indicating that the protein might be in
its inactive unphosphorylated form, or indicate other
post-translational modification or isoforms of ErbB3
(Figure 4C).
Histopathology classification
Based on our results we included ERBB3 in the 6-GeneSig
thus creating a new 7-GeneSig. The 7-GeneSig was refined
to discriminate five subclasses; “NB-r1”, “NB-r2”, “NB-r3”,
“GNB-r4”, and “GN-r4” (Additional file 9). In order to test
the robustness of this 7-GeneSig subgroup classification,
cases from all data sets were reclassified into three histo-
pathology prediction classes “NB” (NB-r1, NB-r2, NB-r3),
“GNB” (GNB-r4), and “GN” (GN-r4) and the reliability of
assignments were investigated. Out of 110 neuroblastic tu-
mours of the Versteeg data set, 82 cases could be success-
fully assigned according to the 7-GeneSig rules (Additional
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rectly assigned according to the 7-GeneSig, and the inter-
rate reliability of assignments was highly significant (Kappa
measure of agreement p = 7.489E-17, Table 2). Five out of
eight GNB tumour types, as well as nine out of ten GN
tumour types were correctly assigned. One GN was pre-
dicted as “GNB” according to the 7-GeneSig (Table 2). In
addition, we also performed a reassignment test on data set
2 comprising one GN, four GNB, and 25 NB tumour types,
which was also significant (inter-rate reliability p = 0.003,
data not shown). Reassignment of r4-cases (from data sets
1, 2 and 3), previously classified as NB, were all assigned to
the “GNB” or “GN” categories by the 7-GeneSig. Also, all
NB cases of data set 4 fell into the NB r1-r3 categories (data
not shown). Conclusively, the histopathology classification
and subgroup assignment by the 7-GeneSig seemed reliable
and highly predictive.
Discussion
Neuroblastic tumours (NT’s) represent a spectrum of
disease, from undifferentiated and aggressive NB to the
differentiated and largely quiescent GN tumours. NB tu-
mours are commonly categorized into three main types
based on numerical and structural genomic alterations,
as well as expression of the neurotrophin receptor TrkA
[10]. In a recent study using Principal Components Ana-
lysis (PCA) however, our data indicated the existence of
four molecular tumour groups, r1-r4 [12]. In the current
study we aimed to further characterize these four mo-
lecular subgroups, and investigated the divergent r4
group in particular. While the r2 (Type 2A) and r3
(Type 2B) tumour subgroups were dominated by cell
cycle-related genes and networks, those were completely
absent in the r4 subgroups (data sets 1–3) and GNB or
GN subtypes (data set 4). The vast majority of the cell
cycle-related genes were linked to the G2/M transition
and spindle assembly checkpoint (e.g. BIRC5, BRCA1,
BUB1B, CCNA2, CCNB1, FANCI, HMMR, KIF15, andTable 2 Histology prediction by 7-GeneSig
Histology
NB GNB GN Total:
Predicted
NB 64 0 0 64
GN 0 1 9 10
GNB 2 5 1 8
Total: 66 6 10 82 nd=28
Measure of agreement (Kappa) p= 7.489E-17
Histology prediction was performed on the Versteeg data set (n = 110). Group
prediction was based upon the standard deviation (sd) of expression of ALK,
BIRC5, CCND1, MYCN, NTRK1, PHOX2B, and ERBB3 according to the rules in
Additional file 9. Out of 110 tumours, 82 were successfully assigned and for 28
tumour cases no group belonging could be determined. The groups were
assigned as follows: "NB" (r1-r3),"GNB" (r4-GNB), and "GN" (r4-GN). The inter-
rate reliability (Kappa) was used to measure the agreement between the
assignments of categories (p= 7.489E-17).MCM2), many of which were found to belong to the
ARACNE-modelled BIRC5-network. Overexpression of
genes involved in mitotic regulation is typical for rapidly
proliferating tumours and would also be expected to be
enriched in the aggressive NB subtypes when compared to
more differentiated quiescent GNB and GN tumours. The
BIRC5 protein is found to stabilize the microtubules in
the chromosomal passenger complex, and knockdown of
BIRC5 causes apoptosis in NB via mitotic catastrophe
[28]. Also, a previous publication show that NB tumours
with genomic aberrations in G1-regulating genes leads to
S and G2/M phase progression [20]. Interestingly, the fork
head box (FOX) gene FOXM1 encoding a protein phos-
phorylated in M phase was significantly up-regulated in r2
and r3 subgroups. FOXM1 activates the expression of sev-
eral cell cycle genes, e.g. AURKB, CCNB1, CCND1, MYC,
and is involved in cell proliferation and malignancy [29].
Several cell cycle and DNA repair genes, including BIRC5,
are suggested to act downstream of N-myc [21,30,31]. In
addition, most of the studied tumour suppressor (TS) candi-
dates were specifically down-regulated in the r3 subgroup,
which is probably explained by them acting downstream of
N-myc. Several of the TS candidate genes are also located in
the 1p36 chromosomal region (e.g. CHD5 and KIF1B
[32-34]), and Del1p is a well-known prognostic marker
highly correlated to MYCN-amplification in NB [35]. One
such N-myc-regulated and 1p36-localized TS candidate is
CDC42, encoding a small GTPase protein. This protein have
a function in cell polarization and growth cone development
in NB cell differentiation, similar to Rac1 and Cux-2, and is
suggested to inhibit neuritogenesis in NB [36]. In concord-
ance to this, we found CDC42 to be the 14th most signifi-
cantly down-regulated gene in the MNA subgroup (r3)
compared to subgroup r2.
The main focus of the study was to define the underlying
regulatory networks of the r4 subgroup. In contrast to the
other three well-known subgroups of NB, the r4 tumours
showed high expression of embryonic development and
nervous system signalling genes. One of the most promin-
ent genes from the differential expression analysis was
ERBB3, encoding a member of the epidermal growth factor
receptor (EGFR) family of receptor tyrosine kinases (RTK’s).
The ARACNE-modelled ERBB3-network was significantly
enriched in the differentially expressed gene lists of the r4
subgroups (data sets 1-3), and this enrichment was also
found in the GNB and GN histopathology categories of
data set 4. Two members of the ERBB3-network, S100B
and SOX10, were among the ten most significantly up-
regulated genes in the r4 subgroups. The S100 calcium
binding protein B (S100B) has long been reported as a
prognostic biomarker of malignant melanoma [37], and a
paired down-regulation of ERBB3 and S100B is observed in
malignant peripheral nerve sheath tumours confirming their
functional relationship [38]. Interestingly, the S100 beta
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be responsible for the lack of NB in Down syndrome pa-
tients by producing growth inhibition and differentiation of
neural cells [39]. The SRY box 10 transcription factor
(Sox10) is a key regulator of the developing nervous system,
and has been shown to control expression of ErbB3 in
neural crest cells [40,41]. A paired overexpression of ErbB3
and Sox10 has been observed in pilocytic astrocytoma (PA)
a common glioma of childhood, which verifies their network
connection found in the current study [42]. Also, Sox10 and
S100 are routinely employed in the pathological diagnosis of
neural crest-derived tumours [43], and Sox10 serves as an
embryonic glial-lineage marker in NT’s [44]. By immunohis-
tochemistry assessment, we found Sox10 to be expressed in
both the schwannian cells and ganglion cells, whereas ErbB3
was found mainly in the mature ganglion cells. We could
also verify the GN-specific expression of ErbB3 by immuno-
blot analysis.
ErbB3 is activated through ligand binding of neuregulin
(NRG), leading to heterodimerization of ErbB3 to other
ErbB members and subsequent phosphorylation. Activated
ErbB3 regulates proliferation through downstream signalling
of the phosphoinositol 3-kinase/AKT survival/mitogenic
pathways [25]. In the current study we found a significant
correlation of ERBB3 to its family members EGFR and
ERBB2 in all four independent data sets. EGFR and ERBB2
were also both found to be significantly up-regulated in all
r4 subgroups as well as in the GNB and GN tumours. Amp-
lification of ERBB3 and/or overexpression of its protein has
been reported in numerous cancers, including prostate,
bladder, and breast. Moreover, loss of ErbB3 function has
been shown to eliminate the transforming capability of
ErbB2 (also known as HER-2) in breast tumours [45]. Al-
though the extent of the role of ErbB3 is emerging, its clin-
ical relevance in different tumours is controversial. There
are a few studies of ErbB/HER receptor expression in neuro-
blastoma, showing that ErbB/HER family members in
neuroblastic tumour biology is interrelated and complex,
but their expression level may present a prognostic factor
for patients outcome [46-48].
The heat map of 25 genes including the 6-GeneSig genes,
ERBB-genes and TS-genes showed a very specific expres-
sion pattern among the different r-subgroups and histo-
pathology categories. The similarity of expression profiles
between the four data sets was striking. The correspond-
ence of the r4 subgroups to the GNB and GN histopath-
ology subtypes was obvious, and ERBB3 appeared as a
clear-cut marker for a GNB/GN-like expression profile. To
demonstrate this further, a new 7-GeneSig (including
ERBB3) was constructed and used in a histopathology re-
assignment classification test. The 7-GeneSig successfully
assigned 100% NB tumours, 62,5% GNB tumours, and 90%
GN tumours into the correct histopathology category
(Kappa measure of agreement p = 7.489E-17, data set 4).Also, all r4-tumour types from data sets 1–3 were catego-
rized as GNB or GN tumours according to the 7-GeneSig.
By these facts we conclude that the NB tumours previously
assigned to the r4 subgroup by the 6-GeneSig, most likely
represent more differentiated NT’s and are seemingly
GNB/GN tumours types. Our study brings out the com-
plexity in classifying neuroblastic tumours. The previously
described unfavourable characteristics and poor outcome
of the r4 tumour group is puzzling [12], but can be
explained by the fact that prognostic subsets of GNB’s exist
[49]. Historically, GNB’s have been the most difficult of the
NT’s to define in a consistent and uniform fashion, because
the number and degree of differentiation of the neuroblastic
cells tend to vary between cases as well as between different
microscopic fields in the same tumour [1]. Moreover, the
data sets used in the current study are probably not truly
population-based, and the r4 subgroups found probably
consist of different proportions of F/UF subsets. In addition,
some tumours may previously have been misclassified as
NB, or the tumour tissue part analysed by microarray may
not be the same as the tissue part that underwent histopath-
ology assessment. Furthermore, it is not clear whether dif-
ferentiation markers are superior to other prognostic factors
in defining outcome. Unfavourable markers such as MNA
and clinical stage may also be present in or among differen-
tiated cells, and mark a poor prognosis by themselves.
ErbB3 also has an important role in differentiation of
Neural crest cell (NCC) lineages during the embryonic de-
velopment [50]. Although ErbB receptors are also found to
mediate proliferation and survival [47,48], the ERBB-profile
found in this study is likely to reflect the phenotype or dif-
ferentiation stage of developing neuronal progenitors. Upon
induction of differentiation, neuronal progenitors may fol-
low a variety of stages of NCC lineages. For example,
neuroblasts in culture are shown to represent an immature
bilineage stage able to progress towards neuronal and glial
fates [44]. Schwannian cells are the principal glia of the per-
ipheral nervous system, whereas neuroblasts differentiate
from neural stem cells and exhibit variable degrees of differ-
entiation up to ganglion cells. In this context, the ERBB-
profile seems to be a marker of ganglionic-neuronal dif-
ferentiation. A recent immunohistochemistry study of
ErbB2 in neuroblastic tumours supports this conclusion
[51]. However, it still remains uncertain whether the r4
subgroup of datasets 1 and 3 are indeed GN or GNB, or if
the ERBB expression profile just marks the gradually dif-
ferentiated NB tumours (encompassing increased levels of
mature ganglion cells). Nevertheless, the results from all
data sets are consistent in regards to the expression profile
of the 25 genes selected for the heat map, strengthening
the robustness of the suggested 7-gene signature. Accord-
ingly, we propose ErbB3 as an excellent marker of neur-
onal differentiation, and suggest mRNA expression
profiling by the 7-gene signature as a complement to
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expression levels for classification needs to be worked out
in more detail, and classification must be based on inter-
national standard cases and assays.
Conclusions
In summary, by differential expression analysis and net-
work modelling we have identified genes and gene net-
works constituting molecular and histological subgroups of
neuroblastic tumours. The primary aim of our study was
to identify genes characterizing the previously unknown r4
subgroup. Our results pinpointed ERBB3 and its network
as one of the most significantly up-regulated genes within
this group. By studying the expression profiles in a broader
range of neuroblastic tumour types, we found the r4 sub-
group to be highly similar to GNB/GN tumour types. The
ERBB-dominating profile found in r4 and GNB/GN tu-
mours was clearly divergent from the cell-cycle-dominat-
ing profile mainly representing NB tumour subgroups
(specifically unfavourable NB subgroups). Our findings in-
dicate that the previously identified r4 subgroup most likely
constitutes GNB/GN tumours or NB tumours with high
content of mature ganglion cells. This study also demon-
strates the importance of performing unsupervised subtype
clustering prior to down-stream analyses. Predefined sub-
groups and supervised clustering studies might give
distorted results if they are based on pools of mixed tumour
histopathology subgroups. In conclusion, we have identified
ERBB3 as a marker of a GNB/GN-like expression profile,
and we suggest a 7-gene expression signature as a comple-
ment to histopathological assessment of neuroblastic tu-
mours. Further studies of ErbB3 and other members of the
ErbB family and their role in neuroblastic differentiation
and pathogenesis are warranted.
Methods
Pre-processing microarray data
Data from five published neuroblastoma expression micro-
array studies run on three different Affymetrix platforms
(HU133A, HGU95Av, and HU133plus2) were used in this
study (Table 1). Raw data files were obtained from Array
Express (www.ebi.ac.uk/microarray-as/ae/) and Gene Ex-
pression Omnibus (www.ncbi.nlm.nih.gov/geo/), or directly
from collaborators. Expression data files were normalized
by gcRMA using Bioconducter (library BioC 2.4) in R 2.9.2
[52] in four separate groups; 1) the De Preter [53] data set
run on the HGU133A Affymetrix platform (17 samples,
preamplified), 2) the McArdle [54] and the Wilzén [55] data
sets run on the HGU133A Affymetrix platform (30 sam-
ples, not pre-amplified), 3) the Wang [56] data set run on
the HGU95Av2 platform (102 samples, not pre-amplified),
and 4) the Versteeg [57] data set run on the HU133plus2
platform (110 samples). For each probe-set, the maximum
expression values over all samples were determined, andprobe-sets which showed very low or no detectable expres-
sion levels were filtered out (log2 expression <5). Next, the
mean log2 expression level for each Gene symbol was cal-
culated to generate “mean-per-gene” data files: 7439 genes
in data set 1, 8106 genes in data set 2, 7542 genes in data
set 3, and 15614 genes in data set 4.
Differential expression analysis
NB samples from the DePreter and McArdle/Wilzén data
sets were divided into four r-subgroups by a 6-gene signa-
ture (further referred to as the“6-GeneSig”) according to
Abel et al., 2011 [12] (Additional file 1). From these two
data sets, 14 (preamplified, De Preter) and 23 (non-preamp-
lified, McArdle/Wilzén) cases respectively were successfully
assigned into one of the four r-groups (Table 1). Differential
gene expression analysis was performed by a two group un-
paired Significance Analysis of Microarray (SAM) test (i.e.
six comparisons) [58]. Gene lists comprising the 1000 most
significantly differentially expressed genes (sorted after the
d-statistic) with a fold change above 2 were exported from
each comparison, from each direction (up or down), and
from each data set, separately (resulting in 12 SAM gene
lists per data set). Next, SAM gene lists from the two differ-
ent data sets were compared, and 12 intersection gene lists
(SAMintersect) were created. Too minimize the variance, a
combined fold change (FCcomb) for each gene in the
SAMintersect gene list was calculated as follows:
FCcomb ¼ FCV 21 FC
V 1
2
where FCi is the fold change in data set i and
V i ¼
SE 2i
SE 21þ SE 22
where SEi is the standard error of the mean log2 expression
values in data
set i.
A combined p-value (Pcomb) for each gene in the
SAMintersect gene list was calculated as follows:
Pcomb ¼ Φ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N1
N1 þ N2
r
Φ−1 P1ð Þ þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N1
N1 þ N2
r
Φ−1 P2ð Þ
 
where Ni is the total number of samples of the two
groups compared by the
d-statistic in SAM, and Pi the corresponding p-value
for dataset i. Φ is the cumulative distribution function of
the standard normal distribution and Φ-1 is its inverse
function.
Based on an approximation of 8000 multiple tests (i.e.
8000 genes), a nominal p-value <6.25E-06 was found to
correspond to an adjusted p-value <0.05 (according to
Bonferroni correction) and was subsequently used as a
cut-off for significance in SAM.
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A large gene regulatory network was constructed from an
independent data set (Wang) of 102 expression profiles
[56]. Mutual information values were estimated with the
ARACNE (Algorithm for the Reconstruction of Accurate
Cellular Networks) algorithm using a p-value cut-off of 1E-
7 [26]. The data processing inequality (DPI) was applied
with a tolerance of 0.15. Gene networks of seven selected
genes were extracted from the global network together
with their immediate gene neighbours. The gene networks
of nearest neighbours were visualized in Cytoscape 2.8.2.
Gene ontology (GO) and Gene Set enrichment analysis
(GSEA)
Ranked SAM gene lists (by d-statistic) from the separate
data sets were investigated for Gene Ontology terms
using BiNGO 2.4 (Biological Network Gene Ontology,
www.psb.ugent.be/cbd/papers/BiNGO/). The Gene Set
Enrichment Analysis (GSEA, www.broad.mit.edu/gsea/)
software was used to investigate whether a gene network
was significantly overrepresented in the different r-
subgroups. The enrichment tests were performed using
seven ARACNE-constructed gene networks ALK (n =
12 genes), BIRC5 (n = 45 genes), CCND1 (n = 22 genes),
ERBB3 (n = 38 genes), MYCN (n = 40 genes), NTRK1
(n = 62 genes), and PHOX2B (n = 67 genes), as well as
4850 MSigDB-curated gene sets (c2, www.broadinstitute.
org/gsea/msigdb/index.jsp, Additional file 6). The GSEA
according to Subramanian et al. [59], was run on the
“mean-per-gene” data files using the following settings:
number of permutations = 1000, permutation type = gene-
set, chip platform = GENE_SYMBOL.chip, enrichment
statistic = weighted, metric for ranking genes =
Signal2Noise, gene list sorting mode = real, gene list order-
ing mode = descending, max gene set size = 500 (the de-
fault), min gene set size = 10 (the default is 15). In addition,
the r3 versus r1 comparisons in data sets 1–3 were investi-
gated according to the gene list sorting mode = abs.
Human tissue samples used for protein expression
validation
Tumours histopathologically classified as GN and NB (data
set 5, Table 1) were used for immunohistochemistry (4 NB
and 4 GN), and immunoblot analysis (4 NB and 5 GN). Tis-
sue from patients was obtained during surgery and stored
in −80°C. Ethical approval was obtained from the Karolinska
University Hospital Research Ethics Committee (Approval
no. 2009/1369-31/1 and 03–736). Informed consent for
using tumor samples in scientific research was provided by
parents/guardians. In accordance with the approval from
the Ethics Committee the informed consent was either
written or verbal. When verbal or written assent was
not obtained the decision was documented in the med-
ical record.Immunohistochemistry
Formalin-fixed and paraffin-embedded (FFPE) tissue
slides were deparaffinized in xylol and rehydrated in
graded alcohols. For antigen retrieval, slides were boiled
in a sodium citrate buffer (pH 6.0) for 10 min, in a
microwave oven. After blocking in 1% bovine serum al-
bumin (BSA) for 20 min, the tissue sections were incu-
bated with primary antibody overnight, Sox10 ([N-20],
Santa Cruz Biotechnology) and ErbB-3 ([RTJ2], Abcam)
respectively, diluted 1:50 in 1% PBSA. Thereafter slides
were rinsed in PBS and endogenous peroxidases were
blocked in 0.3% H2O2 for 10 min. As a secondary anti-
body, anti-mouse-horseradish peroxidase (HRP) and
anti-goat-horseradish peroxidase were used (Invitrogen,
Paisley, UK). All slides were counterstained with haema-
toxylin. To control for non-specific binding, antibody
specific blocking peptides and isotype-matched controls
were used. For colocalization studies of Erb3 and Sox10,
tumor tissue sections were simultaneously stained with
primary antibodies and for fluorescence visualization,
anti-goat Alexa Fluor 594 and anti-mouse Alexa Fluor
488 were used, respectively.
Immunoblot analysis
Tumours were homogenized in RIPA buffer (20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1
mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM
sodium pyrophosphate, 1 mM beta-glycerophosphate, 1
mM Na3VO4, 1 ug/ml leupeptin) with protease inhibitor
cocktail (Roche), 42 mM DTT and 1 mM PMSF. The total
protein concentration was determined using A280 absorb-
ance readings and 100 ug of total protein was diluted in
NuPAGE® LDS sample buffer (Invitrogen) with 50 mM
DTT and denatured for 10 min at 70°C. The samples were
then loaded with a prestained Page Ruler protein ladder
(Thermo-Scientific) on a 4-12% NuPAGE® Bis-Tris poly-
acrylamide gel (Invitrogen) and separated using MOPS
buffer at 200V for 50 min. The proteins were transferred
to PVDF membranes using NuPAGE® transfer buffer
(Invitrogen) and 10% methanol. Following Ponceau
staining to ensure equal loading, membranes were
washed with TBS-T (Tris-buffered saline containing
0.1% Tween 20) and blocked with blocking buffer (5%
milk/TBS-T) for 1 h. The primary antibodies were
added to the membranes and incubated overnight at 4°C.
The following day, membranes were washed with
TBS-T and incubated with secondary antibodies. Fol-
lowing final TBS-T washes, protein detection was
achieved with Pierce Super Signal® West Pico or Femto
Chemiluminescent Substrate (Thermo-Scientific). The pri-
mary antibodies used were anti-ErbB3 [RTJ2] (Abcam,
1:200) and anti-Gapdh (Abcam, #ab8245, 1:10000). The sec-
ondary antibodies used were anti-mouse IgG HRP linked
antibodies (Cell Signaling, #7076, 1:5000), anti-rabbit IgG
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antibodies were diluted in blocking buffer.
Statistical analyses
The expression relationship of ERBB3 to the discrimina-
tive 6-GeneSig (ALK, BIRC5, CCND1, MYCN, NTRK1,
and PHOX2B) and the ErbB family members EGFR,
ERBB2, and ERBB4 were investigated by a Pearson correl-
ation test. The statistical significance of expression levels
of ERBB genes (i.e. EGFR, ERBB2, ERBB3, and ERBB4)
were investigated by Welch t-test. Inter-rater reliability of
group assignments was tested by the Kappa statistic on
crosstabs in SPSS (version 20.0).
Additional files
Additional file 1: The 6-GeneSig subgroup classification rules. Rules
based on standard deviations (SD) of expression values for all samples in
each data set. In order for samples to be successfully assigned into one
of four r-groups, 5 out of 6 expression rules must be met. Shaded cells
indicate rules with no exception for classification into that specific
subgroup.
Additional file 2: SAM results. The table presents the 1000 most
significant genes in each direction from the SAM analyses of four data
sets: 1 (DePreter), 2 (McArdleWilzén), 3 (Wang) and 4 (Versteeg). In
addition, the SAMintersect gene lists are also presented (named
DePreterMcArdleWilzén). Comparisons are named ′12′, ′13′, ′14′, ′23′
etc. corresponding to r2 versus r1, r3 versus r1, r4 versus r1, r3 versus r2,
respectively. Directions of differential expressions are referred to as “up”
and “down”.
Additional file 3: GO results. The Biological Networks Gene Ontology
tool (BiNGO) in Cytoscape was utilized to map the predominant
functional themes of the SAM gene lists. The 10 most significant Gene
Ontology (GO) from terms in each SAM comparison are presented. Gene
lists are divided into three data sets; data set 1 & 2 (DePreterMcArdleWilzén),
data set 3 (Wang), data set 4 (Versteeg), and into two differential expression
directions; "up" or "down". GO-ID: Gene Ontology identification number,
p-val: p-value, corr p-val: corrected p-value, Description: Description of the
gene ontology theme. The "DePreterMcArdleWilzén_12_down" list was too
short (22 genes) to enable the GO term search.
Additional file 4: Correlations of ERBB3 to the 6-GeneSig other
ERBB family members. Left panel: Pearson Correlations of ERBB3 to the
6-gene signature (6-GeneSig) in four data sets separately (1 = De Preter,
2 = McArdle/Wilzén, 3 = Wang, 4 = Versteeg). Right panel: Pearson
Correlations between the four ERBB-genes in four data sets separately.
Positive correlations are marked in grey, and negative correlations are
marked in white. Significance (2-tailed) is marked as follows: *Significant
at the 0.05 level; **Significant at the 0.01 level; ***Significant at the 0.001
level. N = number of cases.
Additional file 5: TS candidate genes. Tumour suppressor genes were
found by the PubMed search term "Neuroblastoma AND tumour
suppressor", and from previous mining of literature lists according to
Vermeulen et al., Lancet Oncol. 2009 July; 10(7): 663–671 (59 gene set)
and Thorell et al., BMC Med Genomics 2009 Aug 17; 2:53. Present in
SAMintersect: genes found in the intersect SAM lists of data sets 1 & 2.
y = yes; n = no.
Additional file 6: Gene networks used for GSEA analysis. The table
presents the gene network members of all c2 curate gene sets (4850 in
total) from MSigDB (www.broadinstitute.org/gsea/msigdb), and seven
ARACNE gene networks used in the GSEA analyses.
Additional file 7: GSEA results. Results of Gene set enrichment analysis
(GSEA) from each comparison and each data set are presented in each
sheet. Data sets 1–3 (DePreter, McArdle/Wilzén, and Wang) comparisonsare according to r-subgroups (r1-r4), and data set 4 (Versteeg)
comparisons are according to histopathology groups; Ganglioneuroma
(GN), Ganglioneuroblastoma (GNB), and Neuroblastoma (NB). Enrichments
were run with 1000 permutations, permutation type = gene set, and
gene list sorting mode = real (scoring both extremes) in descending
order. Results per data set and comparison in each sheet are presented
as follows: NAME = name of the gene set, SIZE = Size of the gene set,
ES = enrichment score, NES = Normalized enrichment score, NOM p-val =
Nominal p-value, FDR q-val = False Discovery Rate, FWER p-val =
Familywise-error rate, RANK AT MAX = The position in the ranked list at
which the maximum enrichment score occurred, LEADING EDGE =
Displays the three statistics used to define the leading edge subset. In
addition, the r3 versus r1 comparisons in data sets 1–3 were
investigated and presented as gene list sorting mode = abs.
Additional file 8: Analyses of the NTRK1 and MYCN gene networks.
Networks for MYCN (n = 40) and NTRK1 (n = 62) were created from the
Wang data set using the ARACNE software (see text for details).
Differentially expressed genes of r-groups are marked by coloured nodes;
red = up-regulated, green = down-regulated. Left panel: Data sets 1 and
2 (DePreter and McArdle/Wilzén) presenting the r3 vs. r1 comparison for
the MYCN- (upper) and NTRK1- networks (lower). Only genes that were
common in both data set 1 and 2 with fold change > 2 were included
(i.e. SAMintersect gene lists). Middle panel: Data set 3 (Wang) presenting
the r3 vs. r1 comparison for the MYCN- (upper) and NTRK1- networks
(lower). Genes included were those present in SAM gene list representing
the 1000 most differentially expressed with fold change > 2 (ranked after
significance). Right panel: Gene set enrichment analysis (GSEA) plots of
the MYCN and NTRK1 networks are according to gene list sorting
mode = real, sorted in descending order. NES = Normalized enrichment
score, NOM p-val. = Nominal p-value, according to the GSEA results (see
Additional file 7). *The NOM p-val. for the MYCN-network is presented
according to gene list sorting mode = abs (see Additional file 7).
Additional file 9: The 7-GeneSig classification rules. Rules based on
standard deviations (SD) of expression values for all samples in each data
set. In order to classify samples into one of the five subgroups, 5 out of 6
expression rules must be met. Shaded cells indicate rules with no
exception for classification into that specific subgroup.
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